Article
Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels -- a study based on therapeutic drug monitoring data
2022-12-08
Abstract excerpt
Atomoxetine is mainly metabolized by CYP2D6 while CYP2C19 plays a secondary role. It is known that patients carrying genotypes encoding decreased/absent CYP2D6 metabolism obtain higher atomoxetine concentrations and are at increased risk of adverse effects. Here, we aimed to investigate the added effects of reduced-function CYP2C19 genotype on atomoxetine concentrations in real-world settings. Serum atomoxetine co...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0600f404-ac3d-5b05-b9ba-66de7e121532
- DOI
- 10.22541/au.167050638.80828727/v1
